Study Name | Study Type | Patients Sort ascending | Status | Primary Endpoint | ||||
---|---|---|---|---|---|---|---|---|
Taglieri et al. | Network Meta-Analysis | 99039 | - | TLF at 12 months and the longest FU available | ||||
SCAAR | All comers registry | 69570 | 24-month FU available | - | ||||
Madhavan et al. | Meta-Analysis | 20701 | - | TLF at mean 30 months | ||||
BIODEGRADE | RCT | 3850 | 36-month FU available | TLF at 18 months | ||||
BIO-RESORT | RCT | 3514 | Completed, 60-month FU available | TVF at 12 months | ||||
SORT OUT IX | RCT | 3151 | 24-month FU available | TLF at 12 months | ||||
SORT OUT X | RCT | 3146 | 12-month FU available | TLF at 12 months | ||||
TICO | RCT | 3056 | Completed, primary endpoint reached | NACE at 12 months | ||||
SMART-CHOICE | RCT | 3000 | Primary endpoint reached | MACCE at 15 months | ||||
BIONYX | RCT | 2488 | 36-month FU available | TVF at 12 months | ||||
BIOSCIENCE | RCT | 2119 | Completed, 60-month FU available | TLF at 12 months | ||||
HOST-IDEA | RCT | 2013 | 12-month FU available | TLF at 12 months | ||||
BIOFLOW-DAPT | RCT | 1948 | 12-month FU available | Composite of Cardiac death, Myocardial Infarction and Definite or probable Stent thrombosis at 12 months | ||||
BIOFLOW-III | Single arm registry | 1356 | Completed, 60-month FU available | TLF at 12 months | ||||
BIOFLOW-V | RCT | 1334 | Completed, 60-months FU available | TLF at 12 months | ||||
BIOSTEMI | RCT | 1300 | Completed, 60-months FU available | TLF at 12 months | ||||
BIOFLOW-IV | RCT | 575 | Completed, 60-month FU available | TVF at 12 months | ||||
ROSES | Single arm registry | 460 | Preliminary results available | TLF at 12 months | ||||
BIOFLOW-II | RCT | 452 | Completed, 60-month FU available | LLL at 9 months | ||||
BIOFLOW-VI | RCT | 440 | Completed, 60-month FU available | LLL at 9 months | ||||
ORIENT | RCT | 372 | 36-month FU available | LLL at 9 months | ||||
HEROES | Single arm registry | 353 | 36-month FU available | DOCE at 12 months | ||||
PRISON-IV | RCT | 330 | Completed, 60-month FU available | LLL at 9 months | ||||
BIOLUX-RCT | RCT | 210 | 18-month FU available | LLL at 6 months | ||||
PREPARE-CALC | RCT | 200 | Completed | Strategy success and LLL at 9 months | ||||
REVELATION | RCT | 120 | Primary endpoint reached | FFR at 9 months | ||||
Hattrick-OCT | RCT | 44 | Primary endpoint reached | Strut coverage at 3 months | ||||
ISAR OCT | RCT | 39 | Primary endpoint reached | Strut coverage at 6 months | ||||
BIOFLOW-I | FIM | 30 | Completed, 12-month FU available | LLL at 9 months |
*a selection of the full clinical program of the Orsiro family.
Clinical data conducted with Orsiro, Orsiro Mission’s predecessor device can be used to illustrate Orsiro Mission clinical outcomes.
© 2022 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.